New GenomeWeb coverage takes a closer look at Carlos Cruchaga and his team’s recent findings on plasma biomarker changes during lecanemab treatment.   Using NULISAseq™, the team identified 34 proteins that changed significantly during treatment, revealing distinct trajectories across biomarkers associated with amyloid, tau, neuroinflammation, and neurodegeneration.   The GenomeWeb story digs deeper into these findings, including the team’s efforts to investigate biomarkers that could help predict amyloid clearance and further characterize treatment response.   Read the full story: na2.hubs.ly/H08xjrH0

We’re proud to sponsor the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), bringing together the global multiple sclerosis community in Toronto.    As researchers and clinicians gather to share the latest advances in MS and related disorders, we look forward to connecting with the community and discussing how ultrasensitive proteomics can help uncover new insights into neurological disease biology.   Visit Alamar Biosciences at Booth 129 to meet our team and learn how NULISA™ is advancing biomarker research in MS and beyond.   Learn more: na2.hubs.ly/H08rQWf0   #MSToronto2026 #MultipleSclerosis #MSResearch #Neurology #Proteomics #Biomarkers #NULISA #AlamarBiosciences

Only 3 days remain to apply for the NULISA™ Immunology Grant Program! Apply now: na2.hubs.ly/H08kHlT0   Four selected research projects will receive access to the NULISAseq™ Immune 340 Panel, including analysis of 86 samples through Alamar Biosciences’ Technology Access Program (TAP). Leverage ultrasensitive, multiplex proteomics to explore key immune pathways, identify potential biomarkers, and uncover new insights into immune-related disease biology.   Applications close Thursday, October 15 at 11:59 PM PT. Submit your application today before the deadline. #ResearchGrant #NULISA #AlamarBiosciences #Immunology #Proteomics #PrecisionProteomics #Grant

Can proteomics help untangle the overlapping pathologies behind mixed dementia? A new CLARiTI initiative will use NULISAseq™ Neuro 220 to profile ~21,000 longitudinal plasma samples from 10,000 participants, alongside clinical, imaging, genetic, and neuropathological data. “We have to disentangle that heterogeneity and see whether we can bring some clarity to it,” says Sterling Johnson of the University of Wisconsin–Madison. By identifying blood protein signatures associated with different neurodegenerative pathologies, the project could help researchers better characterize disease progression and inform future clinical trials. Read the full article: drugdiscoverynews.com/can-21…

🧠 What can eMTBR-Tau tell us about tau pathology and disease progression? Join Alamar Biosciences and Fierce Biotech for an upcoming webinar featuring Nicholas Ashton, PhD (Banner Health) and Sang Won Seo, MD (Samsung Medical Center). Hear the latest research on how eMTBR-Tau relates to tau PET staging and longitudinal clinical progression in Alzheimer’s disease, plus emerging findings across other neurological conditions. Register now: na2.hubs.ly/H08bNPN0

⏳ Only 2 weeks left to apply for the NULISA Immunology Grant Program! Apply by October 15: na2.hubs.ly/H085HPS0 Four research projects will be selected to receive access to the NULISAseq™ Immune 340 Panel through our Technology Access Program (TAP).   Profile ~340 proteins spanning innate and adaptive immunity, including cytokines, chemokines, immune checkpoints, and cell-death pathways, from just 25 µL of plasma or serum. With attomolar sensitivity and broad dynamic range, Immune 340 enables deeper profiling of low-abundance immune mediators alongside more abundant proteins. Advance your immune research with deeper, high-sensitivity proteomic profiling. #Grant #GrantProgram #Immunology #Proteomics #NULISA #ImmunologyGrant

📣 Alamar Biosciences is heading to the 2026 Biomarkers of Aging Conference!   We're excited to join the aging research community for two days of discussions on the latest advances in biomarkers of aging, longevity research, and technologies for measuring biological aging.   Don’t miss Xiao-Jun Ma, Ph.D., Chief Technology Officer at Alamar Biosciences, presenting research enabled by NULISA™ technology. 📅 Monday, October 5 ⏰ 12:20–12:55 PM ET 📍 Auditorium | The Joseph B. Martin Conference Center   Connect with the Alamar team to learn how NULISA™ and ARGO® HT enable ultra-sensitive, multiplex protein detection and deeper investigation of the low-abundance proteome.   Learn more: Biomarkers of Aging Conference 2026 - Alamar Biosciences (na2.hubs.ly/H07ZTkp0)   #AgingResearch #Biomarkers #Proteomics #NULISA

#HUPO2026 is an exciting showcase of the latest proteomics technologies. This year NULISA is featured in several posters and sessions. Visit us at our booth 246 and attend the posters and sessions to explore how Precision Proteomics is impacting health and disease research. Also, don't miss our Industry Lunch Seminar, Tuesday, 29 Sept at 12:15 in Nicoll 1 with Dr. Steve Williams (Alamar Bio), Dr. Mitchell K.P. Lai (National University Health Center, Singapore) and Dr. Yuanbing Jiang (HKUST).

Just published! The first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. Researchers at Washington University School of Medicine in St. Louis used Alamar's NULISAseq™ CNS 120 Panel to analyze more than 2,300 plasma samples, finding that biomarkers associated with amyloid clearance differed from those associated with cognitive decline in patients receiving lecanemab. By measuring brain-derived tau alongside more than 100 additional proteins, investigators were able to track pathology and treatment response in a single assay, uncovering biological changes that may be missed when evaluating only a small number of biomarkers. As anti-amyloid therapies become part of routine care, precision proteomics is opening a new window into researching how patients respond to treatment. Read the full press release: na2.hubs.ly/H080hnS0 #PrecisionProteomics #AlzheimersResearch #Biomarkers #Neuroscience #NULISA

⏰ Coming up tomorrow: Rethinking ALS Biomarkers   There’s still time to register for a closer look at how ultra-sensitive proteomics is advancing ALS research.   Hear from Prof. Alberto Catanese (RWTH Aachen University) and Clare Paterson, PhD (Alamar Biosciences) as they explore emerging insights into ALS biology and the potential of high-sensitivity protein detection to uncover biomarkers that have historically been difficult to measure.   Tune in tomorrow to explore the latest ALS biomarker research, followed by a live Q&A with the speakers.   👉 Register now: na2.hubs.ly/H07ZTgg0

🕛 Happening Tomorrow: IMID Webinar   Don’t miss the opportunity to hear emerging research and biomarker insights across immune-mediated inflammatory diseases (IMIDs).   Join Dr. Chris Wincup (King’s College London), Dr. Felix Wohlrab (Charité – Universitätsmedizin Berlin), and Dr. Jasmine Sim (Newcastle University) as they share new findings generated using NULISA™ technology across multiple IMID indications.   Discover what ultra-sensitive proteomics is revealing about disease biology and shared inflammatory pathways in tomorrow's webinar, then join the conversation during a live expert panel discussion.   🗓️ Thursday, September 24 ⏰ 3:00–5:30 PM BST   Register now: na2.hubs.ly/H07ZTfq0   #Immunology #AutoimmuneDisease #Inflammation #IMID #MultipleSclerosis #IBD #RheumatoidArthritis #Lupus #Asthma

Today is World Alzheimer’s Day 🧠 More than 55 million people worldwide are living with dementia, including over 7 million Americans living with Alzheimer’s disease. At Alamar Biosciences, we recognize the importance of advancing research that deepens our understanding of neurodegenerative disease and helps move the field toward earlier detection and better outcomes. This #WorldAlzheimersDay, we join the global community in raising awareness and supporting everyone impacted by Alzheimer’s and other dementias. Learn more about these tips from the @alzassociation: 10 Early Signs and Symptoms of Alzheimer’s & Dementia: bit.ly/3V54niD Ways to Support Brain Health: bit.ly/4hkuERi #WorldAlzheimersDay #AlzheimersAwareness #AlzheimersResearch #Neuroscience #Proteomics

📍 Singapore, we're coming to HUPO 2026!   Experience what high-sensitivity, multiplex proteomics can unlock at the 2026 HUPO World Congress, the premier international gathering for the global proteomics community. Connect with us at Booth 246 to see the NULISA™ and ARGO® HT platforms in action and learn how they can accelerate your research.   Join us on Sept 29 for our Industry Lunch Symposium featuring Steve Williams (Alamar Biosciences), Mitchell K.P. Lai (National University Health System, Singapore), and Yuanbing Jiang (The Hong Kong University of Science & Technology) presenting new data on plasma proteomics applications in Alzheimer's disease and dementia research.   🗓 Tuesday, September 29 ⏰ 12:15–1:15 PM SGT 📍 Nicoll 1   👉 Learn more: na2.hubs.ly/H07StkB0   #NULISA #HUPO2026 #Proteomics #BiomarkerDiscovery #PrecisionMedicine

🔬 What can ultra-sensitive proteomics reveal about immune-mediated inflammatory diseases?   Join Dr. Chris Wincup (King’s College London), Dr. Felix Wohlrab (Charité – Universitätsmedizin Berlin), and Dr. Jasmine Sim (Newcastle University) for an upcoming webinar exploring emerging biomarker insights across lupus, neuromyelitis optica spectrum disease (NMOSD), and rheumatoid arthritis using ultra-sensitive NULISA™ technology.   Hear new findings, gain insight into shared biological and inflammatory pathways across diseases, and discover how highly multiplexed protein profiling is helping uncover biology that was previously difficult to detect.   Don’t miss the latest insights shaping IMID biomarker research.    Register now to join the discussion: na2.hubs.ly/H07Q3Vl0… (na2.hubs.ly/H07Q40c0)

Our NULISA™ Certified Service Provider network continues to grow! 🎉   We’re pleased to introduce attyloid as our newest Certified Service Provider, expanding access to NULISA™ technology and expertise for the biopharma research community.   attyloid is a specialized bioanalytical CRO providing ultrasensitive biomarker services for preclinical and clinical research. Combining NULISA™ technology with extensive translational biomarker expertise, their team supports biopharma partners across disease areas—from study design through scientific data interpretation.   We look forward to seeing how attyloid helps researchers leverage ultrasensitive biomarker analysis to advance their studies.   Learn more about attyloid: Ultra-sensitive CNS biomarker profiling | NULISA (na2.hubs.ly/H07PxbH0) Explore our CSP network: Alamar Certified Service Providers | Protein Biomarker Assays (na2.hubs.ly/H07Pxbn0)

What can emerging biomarkers reveal about ALS biology? Join our upcoming webinar to learn how ultrasensitive multiplex proteomics is helping researchers uncover molecular signatures of neurodegeneration, inflammation, and disease progression. Register: na2.hubs.ly/H07D5d40

🔬 Have an immune-focused research project in mind? Apply for the NULISA Immunology Grant Program. Four projects will be selected to receive access to the NULISAseq™ Immune 340 Panel through our Technology Access Program (TAP). Apply by Oct 15: na2.hubs.ly/H07C0D_0

Join Caroline Chan, PhD (Alamar Biosciences) and Katharina Stracke, PhD (GeneWorks) for a webinar exploring how the NULISAseq™ Neuro 220 Panel is advancing neurological disease and biomarker research.   👉 Register here: na2.hubs.ly/H07y7vH0

In our latest Biomarker Edge blog, Alamar CSO Stephen Williams, MD, PhD, explores why amyloid alone doesn’t tell the whole Alzheimer’s story—and how direct measurement of eMTBR-Tau could help address a critical gap in blood-based Alzheimer’s research. 🔗 na2.hubs.ly/H07xrJl0